Background
==========

Delayed *Plasmodium falciparum* response to artemisinin is reported in Southeast Asia, and may spread to other, more intensely malaria-endemic areas. Artemisinin compounds contribute rapid parasite killing and faster clearance to artemisinin-containing combination therapy (ACT). Artemisinin tolerance/resistance manifests itself with slower parasite clearance, while ACT remain generally effective both clinically and parasitologically \[[@B1]-[@B4]\]. Genomic studies are underway, which have generated so far two sets of putative markers of artemisinin resistance - K13-propeller polymorphism \[[@B5]\], and a SNP in the gene encoding a DNA repair protein RAD5 on chromosome 13 (and possibly also on chromosome 10) \[[@B6]\]. An *in vitro* assay (Ring Stage Assay) has also focused on the very early phases of the ring-stage parasite \[[@B7]\]. However, as of today, in the clinic as well as in the field the parasite clearance time (PCT) and its related clinical phenotype (delayed PCT) remain the best practical surrogates of artemisinin *in vivo* resistance \[[@B8]\]; the problem is that the frequent sampling (every six or eight hours) required to measure PCT accurately and to estimate the parasite clearance half-life \[[@B9]\] is practically difficult even in research settings. Easier methods are needed for both research and routine purposes. For example, failure to clear by Day 3 (72 hours post-treatment start) is proposed as a simple and accurate predictor of treatment failure \[[@B10]\], requiring a single time-point and thus limiting the workload in resource-limited settings.

Applying these and other measures both retrospectively and prospectively to commonly-used ACT will help understand trends and detect changes early enough to prompt effective responses to contain the spread of resistance. Artesunate-amodiaquine (ASAQ) is the second most commonly used ACT in the world (the first-line treatment in 22 out of 44 sub-Saharan African countries); more than 200 million treatments of ASAQ Winthrop have been distributed in Africa since the medication became available in 2007 \[[@B11]-[@B13]\]. While ASAQ is generally effective, the decreasing efficacy of AQ single-agent treatment have been reported in some sub-Saharan African settings \[[@B14],[@B15]\]. Should artemisinin resistance occur there, it is expected to result soon in treatment failures, particularly in subjects with partial immunity, such as children in high-transmission areas, or patients of all ages in low-transmission areas. Monitoring ASAQ efficacy, particularly in these groups, has therefore become all the more important.

Greater understanding of factors influencing parasite clearance is crucial, and requires the analysis of pooled data from individual patient records. Therefore, this study collected and analysed a large sample (over 15,000 patients) of individual patient data (of whom approximately three-quarters were children under six years of age) from clinical trials conducted in sub-Saharan Africa between 1999 and 2009.

Studies such as this will help provide the foundations for further analyses of parasite clearance trends across sub-Saharan malaria-endemic countries.

Methods
=======

Study sites, design and patients
--------------------------------

The database was constructed from studies identified through a systematic review of clinical trials and personal contacts. To be included, efficacy or tolerability monitoring studies had to have been conducted in sub-Saharan Africa including any formulation of ASAQ to any other single or combination treatment of uncomplicated falciparum malaria (non-severe or non hyperparasitaemic) with follow-up of at least 28 days. For the studies meeting these criteria, investigators were contacted to provide individual patient data and the datasets received were examined for inclusion \[[@B16]\].

Study endpoints
---------------

Out of the 27 studies included (conducted between 1999 and 2009), three were multi-country studies \[[@B17]-[@B19]\], two studies compared ASAQ fixed and loose combination \[[@B20]-[@B22]\] and three studies were non-comparative (in Sierra Leone \[[@B23]\] and Senegal \[[@B24],[@B25]\]). Details of the studies can be found elsewhere \[[@B26]-[@B40]\]. There was one unpublished study conducted in RDC (Cohuet, unpublished). The analysis of parasite clearance was by modified intent-to-treat (ITT), including all participants who were randomized and received the study medications. The primary endpoint in all the studies included in the analysis was parasitological efficacy, except one study about tolerability \[[@B22]\]. Follow-up ceased at the time of parasitological failure (either primary or recurrence), loss to follow-up, protocol violation and no data were recorded thereafter. Parasitaemia was recorded at enrolment (Day 0) and post-treatment from Day 1 through Day 28, but sampling schedules varied across studies during the first seven days, with Day 1 or Day 2 not recorded in all. Consecutive parasite slide results (Day 0, Day 1, Day 2, Day 3, Day 7) were available at 18 sites from five randomized controlled trials (RCT) \[[@B17]-[@B19],[@B26],[@B27]\].

Definitions and analyses
------------------------

Table [1](#T1){ref-type="table"} summarizes the measures and analyses conducted. The risks of delayed parasite clearance by Day 2 and Day 3 and parasite clearance failure were analysed as binary variables using age (continuous in years), baseline parasitaemia (log transformed) as continuous variables, anaemia (binary variable, haemoglobin \< 10 g/dL), study year (continuous) and study (categorical). The parasite reduction ratio on Day (n) was defined as: parasitaemia before treatment/parasitaemia on Day (n).

###### 

Definitions

  **Measure**                                              **Definition**                                                                                                                                                                                                                 **Population**                                                                                         **Analysis**
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------
  Parasite clearance                                       Patients' conversion from a positive to a negative parasite slide within 7 days post-treatment start (independent of whether it was sustained throughout the entire duration of follow-up or there was a recurrent episode).   All studies, whether comparative or not (n = 15,017)                                                   Observed median time of parasite clearance
  Delayed parasite clearance                               \- Parasitaemia positive on                                                                                                                                                                                                    Prevalence, risks by multivariate analysis                                                             
  `o` Day 2                                                                                                                                                                                                                                                                                                                                                                                      
  `o` Day 3                                                                                                                                                                                                                                                                                                                                                                                      
  Parasite clearance failure                               \- Day 2 parasitaemia \> pre-treatment parasitaemia                                                                                                                                                                                                                                                                                   
  \- Day 3 parasitaemia \>25% pre-treatment parasitaemia                                                                                                                                                                                                                                                                                                                                         
  \- Consecutive positive slides up to Day 7                                                                                                                                                                                                                                                                                                                                                     
  Parasite reduction ratio                                 Relative difference (referent: parasite before treatment)                                                                                                                                                                      ASAQ groups (n = 2,355) where parasite densities were measured once daily from Days 0 to 3 and Day 7   Reduction rate
  Predicted time of parasite clearance                     Modelling the time of parasite clearance                                                                                                                                                                                                                                                                                              Predict the time of parasite clearance using the parasitaemia before treatment and the proportions of positive patients

The curve of the proportions of patients remaining parasitaemic during follow-up was fitted using logistic regression to give an estimate for clearance time. The fitted model for the logit of the proportion of parasitaemic patients over time and expressed in hours from the logistic regression:

$$\begin{array}{l}
{p\left( \text{day} \right) = \text{Logit}\ \left( {\text{constant}–a*\left( {\text{day} + 1} \right)} \right)} \\
{\text{with}\ p\left( 0 \right) = \text{Logit}\ \left( \text{constant} \right)} \\
{\text{pPCT}\ \left( \text{hour} \right) = \left( {\text{Logit}\ \left( - \text{constant}/a \right)–1} \right)*24} \\
\end{array}$$

In order to simplify the calculations of the predicted parasite clearance time ((pPCT), for a patient or a group of patients using the median time parasite clearance) the patient population was classed into ten pre-treatment parasite densities categories. A logistic model was fitted for each group and the corresponding predicted PCT was calculated, and once the results of predicted PCT for the ten groups were obtained, a simple logarithmic model was fitted with the aggregated results.

The risks, presented as adjusted risks ratios (AOR), were assessed by logistic multivariate analysis with random effect on the site in an attempt to account for potential statistical heterogeneity while controlling for age (continuous), parasitaemia before treatment (log-transformed), anaemia (binary), and year (continuous). Categorical data were compared using the Chi-square or the Fisher exact test as appropriate. The Spearman test was used to analyse the relationship between clearance reduction and pre-treatment parasitaemia. Confidence intervals (CI) were calculated at 95% and statistical significance was set at p-value \<0.05.

Ethical issues
--------------

All studies had been approved by the relevant ethics and institution review committees as reported in the individual papers.

ASAQ treatment regimens
-----------------------

The majority of the patients were treated with individually formulated AS and AQ. The target dose was AS 12 mg/kg over three days and AQ 30 mg/kg over three days except in Uganda where AQ was given at 25 mg/kg (Day 0: 10 mg/kg, Day 1: 10 mg/kg, Day 2: 5 mg/kg). The loose combinations of ASAQ were dosed based on body weight, while in four studies the fixed dose combination (FDC) ASAQ was based on age and weight range \[[@B19]-[@B22]\]. The FDC was also given either once or twice a day \[[@B19]\].

ASAQ FDC (Coarsucam™ Winthrop® Sanofi Aventis); AS 25 mg/AQ 67.5 mg one tab/day for three days in children 5--8.9 kg; AS 50 mg/AQ 135 mg one tab/day for three days in children 9--17.9 kg; AS 100 mg/AQ 270 mg one tab/day for three days in children 18--35.9 kg.

Comparator treatment regimens
-----------------------------

i\. ACT: artemether-lumefantrine (AL)(20 mg artemether/120 mg lumefantrine) given according to weight as one (5--14 kg), two (15--24 kg), three (25--34 kg), and four (≥35 kg) tablets given twice daily co-administrated with fat for three days; Coartem™, Novartis); dihydroartemisinin-piperaquine (DP) was given once daily over three days, at the standard dosage of 2.25 mg/kg and 18 mg/kg of dihydroartemisinin-piperaquine, respectively, rounded up to the nearest half tablet (two formulations were used: 20 mg dihydroartemisinin + 160 mg piperaquine and 40 mg dihydroartemisinin +20 mg piperaquine, Eurartesim™, Sigma-Tau, and in Rwanda, Artekin™, Holley); AS + sulphadoxine- pyrimethamine (SP)(AS 4 mg/kg/day; SP 25 mg/kg of sulphadoxine and 1.25 mg/kg of pyrimethamine administered in a co-formulated tablet as a single dose);

ii\. Non-ACT: AQ + SP (AQ 10 mg/kg/day for three days and SP 25 mg/kg of sulphadoxine and 1.25 mg/kg of pyrimethamine administered in a co-formulated tablet (SP) as a single dose); chloroquine (CQ)(25 mg/kg over three days) and SP; AQ monotherapy (10 mg/kg/day for three days); AS monotherapy (AS 12 mg/kg over five days).

Results
=======

Overall 15,017 patients treated for uncomplicated *P. falciparum* malaria at 44 sites in 20 sub-Saharan African countries were included in the analysis (Figure [1](#F1){ref-type="fig"}). The proportion of patients treated with ASAQ was 51% (n = 7,660) *vs* 49% (n = 7,357) on comparator treatments; 31% (4,848/15,017) of the patients had complete parasitaemia data every 24 hours up to Day 3 and then Day 7 (2,355 in ASAQ and 3,493 in comparator groups). Overall, the proportion of children under six years of age was 77%, and the overall geometric mean parasitaemia pre-treatment was 16,964/μL (Table [2](#T2){ref-type="table"}).

![Flow chart, number of patients with parasitaemia results and daily results from Day 0 to Day 3 and Day 7.](1475-2875-13-114-1){#F1}

###### 

Patients at enrolment

  **Year**   **Site**                     **Total**   **Under six years old**   **Treatment**   **Parasitaemia**                   
  ---------- ---------------------------- ----------- ------------------------- --------------- ------------------ ------ -------- -----
  2004       Angola-Caala 2004            137         137                       100             69                 68     29,180   28
  2003       Angola-Kuito 2003            187         187                       100             97                 90     19,216   61
  2008       Burkina faso - Nanoro 2008   810         810                       100             295                515    20,831   83
  2005       Burkina Faso Puytenga 2005   890         824                       93              890                NA     15,210   76
  2006       Cameroon 2006                166         79                        48              110                56     24,627   8
  2004       Congo-Kindamba 2004          298         298                       100             101                197    25,890   64
  2008       Gabon - 2008                 226         226                       100             80                 146    22,265   69
  1999       Gabon 1999                   220         119                       54              110                110    22,537   NA
  2004       Guinee-Dabola 2004           220         220                       100             110                110    37,493   73
  1999       Kenya 1999                   400         346                       87              200                200    31,095   61
  2009       Kenya 2009                   54          0                         0               54                 NA     12,181   2
  2009       Liberia 2009                 1300        302                       23              648                652    1,340    11
  2006       Madagascar 2006              179         76                        42              119                60     9,159    19
  2004       Mali Bancouna 2004           753         714                       95              252                501    15,468   44
  2006       Mali Bougoula 2006           203         134                       66              135                68     22,183   51
  2008       Mozambique - Manhica 2008    420         420                       100             210                210    39,023   62
  2008       Nigeria - Afokang 2008       261         261                       100             92                 169    18,361   72
  2008       Nigeria - Pamol 2008         233         233                       100             82                 151    18,177   73
  2003       RDC Boende 2003              279         279                       100             136                143    24,170   57
  2002       Rwanda Mashesha 2002         122         122                       100             61                 61     14,729   45
  2004       Rwanda Mashesha 2004         269         269                       100             89                 180    20,454   39
  2002       Rwanda Rukara 2002           95          95                        100             49                 46     25,855   40
  2004       Rwanda Rukara 2004           270         269                       100             89                 181    36,868   31
  2002       Rwanda-Kicukiro 2002         91          91                        100             48                 43     13,457   31
  2004       Rwanda-Kicukiro 2004         223         223                       100             74                 149    36,515   28
  2000-5     Sen-Djembeye 2000-5          137         18                        13              137                       25,992   8
  1999       Senegal 1999                 321         123                       38              160                161    40,386   NA
  2006       Senegal 2006                 392         11                        3               264                128    7,991    47
  2000-5     Sen-Mlomp 2000-5             723         74                        10              723                NA     46,328   3
  2000-5     Sen-Oussouye 2000-5          208         106                       51              208                NA     19,142   NA
  2004       Sierra Leone Kailahun 2004   126         126                       100             126                NA     27,116   56
  2003       South Sudan Nuba 2003        161         161                       100             80                 81     21,964   31
  2003       Sudan Malakal 2003           269         269                       100             134                135    22,881   86
  2008       Uganda - Mbarara 2008        319         319                       100             160                159    23,431   51
  2003       Uganda Amudat 2003           212         212                       100             106                106    18,410   49
  2004       Uganda Tororo 2004           541         508                       94              194                347    18502    71%
  2005       Uganda Tororo 2005           408         388                       95              204                204    21,480   40
  2004       Uganda-Apac-2004             542         516                       95              174                368    11,701   64
  2004       Uganda-Arua-2004             534         509                       95              174                360    23,927   63
  2003       Uganda-Jinja-2003            543         370                       68              189                354    34,337   40
  2006       Uganda-Kampala-2006          730         358                       49              242                488    10,581   11
  2008       Zambia - Ndola 2008          245         245                       100             85                 160    36,401   85
  2002       Zanzibar Kivunge 2002        297         296                       100             148                149    16,500   78
  2002       Zanzibar Micheweni 2002      105         105                       100             54                 51     16,777   87
             Total                        15017       11550                     77              7660               7357   16,964   50

Legend: NA, non-applicable.

Parasitaemia on Day 2 and Day 3
-------------------------------

Delayed parasite clearance, defined as the proportion of patients still parasitaemic on Day 2 or Day 3 (analysed as a binary variable) under ASAQ treatment in comparative and non-comparative trials was analysed in 44 sub-Saharan African sites over the period 1999--2009.

The proportion of patients on ASAQ who were still parasitaemic on Day 2 was 8.6% (603/7,020, 95% CI 7.9-9.3%) and ranged from 1.0% in Burkina Faso-Nanoro (2008) and Congo-Kindamba (2004) to 57.1% in DRC-Boende in 2003 (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Using multivariate logistic regression with random effect on site and controlling for treatment, the risk factors for a patient to remain positive on Day 2 were higher parasitaemia before treatment (AOR 2.12, 95% CI 1.91-2.35, p = 0.001) and anaemia (AOR 1.22, 95% CI 1.07-1.38, p = 0.001); no significant difference in the risk of being parasitaemic on Day 2 was detected in RCT comparing ASAQ to other ACT: AL (p = 0.245), DP (p = 0.762), AS + SP (p = 0.291), whereas patients treated with non-ACT were at higher risk: AQ + SP (AOR 14.53, 95% CI 11.36-18.59, p = 0.001), CQ + SP (AOR 20.10, 95% CI 15.07-26.82, p = 0.001), or AQ (AOR 21.63, 95% CI 12.73-36.75, p = 0.001).

The proportion of patients treated with ASAQ who were still parasitaemic on Day 3 was 1.5% (116/7,550, 95% CI 1.2-1.8%, of whom 44 in RDC-Boende), ranging from 0% in many various sites across sub-Saharan Africa to 55.9% in DRC-Boende. Using multivariate logistic analysis with random effects on sites, younger patients (AOR 0.94, 95% CI 0.90-0.98, p = 0.005) and patients with higher parasitaemia at enrolment (AOR 2.43, 95% CI 1.98-3.00, p = 0.001) were at higher risk of remaining parasitaemic on Day 3. Compared to ASAQ, the risk of being parasitaemic on Day 3 was higher for patients treated with a non-ACT: AQ + SP (AOR 15.70, 95% CI 7.43-33.16, p = 0.001), AQ (AOR 16.38, 95% CI 7.82-34.34, p = 0.001), CQ + SP (AOR 72.56, 95% CI 33.70-156.23, p = 0.001), while no significant difference was detected with other ACT (AL, p = 0.993; DP, p = 0.525; AS + SP, p = 0.190) (Figure [2](#F2){ref-type="fig"}).

![**Delayed parasitaemia (Day 3) forest plot, artesunate/amodiaquine*vs*comparator treatments.** AL: artemether-lumefantrine; AOR: adjusted odds ratio using multivariate logistic regression with random effects; AQ: amodiaquine; AS: artesunate; CQ: chloroquine; DP: dihydroartemisinin-piperaquine; fdc: fixed dose combination; na: not applicable; SP: sulphadoxine-pyrimethamine.](1475-2875-13-114-2){#F2}

Parasite clearance failure
--------------------------

Overall, patients treated with an ACT were at lower risk of parasite clearance failure by Day 7 (AOR 0.03, 95% CI 0.01-0.12, p = 0.001, stratified by site) compared to non-ACT (Table [3](#T3){ref-type="table"}). The proportion of patients treated with ASAQ who had a parasite clearance failure was 0.2% (15/7,550, 95% CI 0.1-0.3%), mostly from one site (RDC-Boende). Using multivariate analysis with random effect on site, higher parasitaemia at enrolment (AOR 2.31, 95% CI 1.60-3.35, p = 0.001) was the only risk detected for parasite clearance failure.

###### 

Proportion of patients with a parasite clearance failure by Day 7 and by treatment groups

  **Treatment**   **Parasite clearance failure (number)**   **Total number of patients**    **Parasite clearance failure**        
  --------------- ----------------------------------------- ------------------------------ -------------------------------- ----- ------
  ASAQ            15                                        7,660                                        0.2                 0.1   0.3
  AL              3                                         2,391                                        0.1                 0.0   0.4
  DP              1                                         1,132                                        0.1                 0.0   0.5
  AS + SP         26                                        1,005                                        2.6                 1.7   3.8
  AQ              23                                        621                                          3.7                 3.7   7.4
  AQ + SP         9                                         1,257                                        0.7                 0.3   1.3
  AS              0                                         252                                          0.0                 0.0   1.5
  CQ + SP         78                                        699                                          11.2                8.9   13.7
  Total           153                                       15,017                                       1.0                 0.9   1.2

Parasite reduction ratio
------------------------

Overall, in studies treating with ASAQ and recording daily parasitaemia (n = 2,355), the parasite reduction ratio (parasitaemia before treatment/parasitaemia on day (n)) was 93.9% by Day 1 and 99.9% by Day 2 (Table [4](#T4){ref-type="table"}). The parasite reduction ratio ranged on Day 1 from 77.1% in Mozambique to 99.2% in Kenya with a significant correlation between clearance reduction on Day 1 and pre-treatment parasitaemia (r = 0.098, p = 0.001, Spearman test, individual data).

###### 

Clearance reduction, artesunate/amodiaquine groups

  **Country site**             **Parasitaemia, geometric mean**   **N**    **Parasite reduction ratio (individual data)**                    
  ---------------------------- ---------------------------------- ------- ------------------------------------------------ -------- -------- --------
  Burkina faso - Nanoro 2008   21,185                             295                          97.8%                        100.0%   100.0%   100.0%
  Cameroon 2006                24,129                             110                          97.0%                        100.0%   100.0%   100.0%
  Gabon - Fougamou 2008        21,117                             80                           98.6%                        100.0%   100.0%   100.0%
  Gabon 1999                   20,867                             108                          98.2%                        100.0%   100.0%   100.0%
  Kenya 1999                   30,040                             199                          94.5%                        99.9%    100.0%   100.0%
  Kenya 2009                   12,193                             54                           99.2%                        100.0%   100.0%   100.0%
  Madagascar 2006              9,648                              119                          98.9%                        100.0%   100.0%   100.0%
  Mali Bougoula 2006           23,744                             135                          93.8%                        99.9%    100.0%   100.0%
  Mozambique - Manhica 2008    35,924                             210                          77.1%                        99.8%    100.0%   100.0%
  Nigeria - Afokang 2008       20,326                             92                           96.3%                        99.7%    100.0%   100.0%
  Nigeria - Pamol 2008         17,329                             82                           97.9%                        99.8%    100.0%   100.0%
  Senegal 1999                 41,753                             160                          89.5%                        99.8%    100.0%   100.0%
  Senegal 2006                 20,201                             264                          91.4%                        99.7%    100.0%   100.0%
  Uganda - Mbarara 2008        27,262                             160                          98.4%                        100.0%   100.0%   100.0%
  Zambia - Ndola 2008          35,887                             85                           91.9%                        100.0%   100.0%   100.0%
  Zanzibar Kivunge 2002        20,625                             148                          95.7%                        100.0%   100.0%   100.0%
  Zanzibar Micheweni 2002      18,236                             54                           95.2%                        99.7%    100.0%   100.0%
  Total                        23,596                             2355                         93.9%                        99.9%    100.0%   100.0%

Predicted time of parasite clearance
------------------------------------

The number of patients included in RCT at 17 sites with complete parasitaemia record (every 24 hours from Day 0 to Day 3 plus Day 7) was 4,848 of whom 2,355 were treated with ASAQ and 2,493 with a comparator drug.

Using logistic regression, the predicted time of parasite clearance was overall ≈ 31 hours for a median baseline parasitaemia of 27,125/μL, ranging from ≈ 19 hours for patients with parasitaemia before treatment \<2,500/μL to ≈ 37 hours for patients with parasitaemia \>100,000/μL (Table [5](#T5){ref-type="table"}).

###### 

Predicted parasite clearance time by groups of parasitaemia before treatment and intervals, artesunate/amodiaquine treatment

  **Parasitaemia at enrolment (μL)**    **N**   **Median**          **Observed**                   **pPCT**         
  ------------------------------------ ------- ------------ ------ -------------- ----- ---- ---- ---------- ------ ------
  \<2,500                                110      2,030      100%       24%        2%    1%   0%     19.0      NA     NA
  2,500-5,000                            227      3,680      100%       44%        7%    1%   0%     24.4     21.7   26.7
  5,000-10,000                           294      7,290      100%       58%        10%   1%   0%     28.2     23.8   32.5
  10,000-20,000                          361      14,261     100%       65%        6%    1%   0%     29.1     25.1   36.2
  20,000-30,000                          261      25,044     100%       68%        10%   0%   0%     30.8     25.7   35.8
  30,000-50,000                          362      39,250     100%       73%        9%    1%   0%     31.6     27.2   37.1
  50,000-75,000                          252      61,372     100%       75%        12%   2%   0%     32.9     26.8   37.5
  75,000-100,000                         159      86,925     100%       79%        13%   0%   0%     34.0     29.8   39.9
  \>100,000                              329     144,357     100%       84%        18%   3%   1%     37.3     33.1   40.7
  TOTAL                                 2,355     27,125     100%       67%        10%   1%   0%     30.8     25.8   41.8

Legend: pPCT, predicted parasite clearance time.

Using the predicted PCT from the ten categories of levels of baseline parasitaemia, a logarithmic relationship was detected between the observed median baseline parasitaemia and the corresponding predicted PCT (Figure [3](#F3){ref-type="fig"}A). The fitted curve was a logarithmic relationship defined by:

$$\begin{array}{l}
{\;\text{pPCT} = 3.614*\ln\left( {p0} \right)–6.135;r^{2} = 0.94} \\
{\;\text{where}:\text{pPCT} = \text{predicted}\ \text{parasite}\ \text{clearance}} \\
{\text{time}\ \text{expressed}\ \text{in}\ \text{hours};\text{and}\ p0 = \text{parasitaemia}} \\
{\text{at}\ \text{enrolment}\ \left( \text{pre} - \text{treatment} \right)} \\
\end{array}$$

![**Fitted curve of parasite clearance and intervals, artesunate/amodiaquine treatment. A**: pPCT, predicted parasite clearance time. **B**: pPCT, predicted parasite clearance time.](1475-2875-13-114-3){#F3}

The lower and upper bounds of the interval were fitted using sites where the overall proportion of parasitaemic patients were \<10% on Day 2 for the lower bound and \>10% for the upper bound with a coefficient of determination (r^2^) of 0.88 for both adjustments (Figure [3](#F3){ref-type="fig"}B). The 10% threshold was in keeping with WHO recommendations \[[@B41]\].

Discussion
==========

This individual patient data analysis of parasite clearance was conducted on a large sample (n \~15,000) of uncomplicated malaria treatments (predominantly paediatric; three-quarters less than six years old) from 44 sites and 20 sub-Saharan African countries with different levels of endemicity, covering the decade 1999--2009.

This analysis shows that rapid *Plasmodium falciparum* clearance continues to be achieved in sub-Saharan African patients treated with ACT, and in particular with ASAQ, although direct within-site comparisons are not available; it has therefore benchmarking value as reference for future studies. This study also presents a prediction formula for PCT as a pragmatic tool adapted for studies with binary data (not quantitating parasite densities) and once-daily sampling, such as those that would be done at the typical study site in peripheral settings and in routine surveillance by control programmes. This prediction could apply to groups of patients as well as to the individual patient.

These results confirm the correlation between pre-treatment parasitaemia and PCT \[[@B10]\], and offer an easy way to calculate the typical PCT (in hour) using parasitaemia before treatment (p0) with ASAQ or other equivalent treatments (pPCT = 3.614\*ln(p0) -- 6.135, r^2^ = 0.94). There was also a (weaker) correlation between parasitaemia before treatment and the parasite reduction ratio (PRR) at 24 h.

Monitoring treatment response and detecting artemisinin resistance as early as possible have become a major issue in malaria control. The rate at which treatment clears parasites within the first few days is at present the most useful practical test for ACT, as early response to treatment relies predominantly on the parasite response to artemisinin, independent of whether parasites are later cleared for good through the combination of the longer-lived companion drug and the host's immune response.

The present analysis focused on initial response to ACT treatment, as a proxy for artemisinin resistance and failure, and aimed to identify variables that were independently associated with persistent parasitaemia on Days 2 and 3 in settings where artemisinin resistance has probably not yet emerged.

Within the period covered by these studies, there was no indication of delayed response to ACT. ACT cleared parasites rapidly leaving very few patients with a low parasitaemia on Day 3 (first day after the completion of the three-day ACT regimen). In particular, with ASAQ the parasite reduction ratio was 93.9% by Day 1 and 99.9% by Day 2; only 1.5% of the patients were still positive on Day 3 (against a proposed threshold of 3% indicating delayed response \[[@B10]\]). These data confirm that pre-treatment parasitaemia is a risk factor for failing to clear parasites on Day 2 and 3. They also show a clear contribution of artemisinins to the speed of action: ACT performed significantly better than non-ACT (whether combinations or single-agent treatments); no difference was detected between ACT (whether the artemisinin derivative was artesunate, artemether or dihydroartemisinin).

Anaemia was an additional risk factor for failing to clear parasites by Day 2; younger patient's age for Day 3. The only exception was the study conducted in DRC-Boende (Cohuet, unpublished) which had a high proportion of parasite clearance failures with both ASAQ and AL. These findings are difficult to explain and should be taken with caution, but one cannot exclude that there might also have been a focus of resistant *Plasmodium falciparum* in the DRC. No subsequent studies are available to confirm or belie this original study. Understanding the dynamics of parasite clearance could help detect early signs of artemisinin resistance and distinguish biologically meaningful changes in early parasite clearance over time from changes that may be due to the role of effect modifiers like higher pre-treatment parasitaemia, young age and anaemia by applying multivariate analysis.

Consistently with previous results \[[@B10]\] and the first-order process of parasite clearance, there was a logarithmic correlation between patients' pre-treatment parasitaemia and their pPCT; while developed using ASAQ data, it was applied satisfactorily to other ACT within this database as well as other studies. For example, in a study conducted in Mali \[[@B42]\] where parasitaemia was tested with frequent screenings (every eight hours) in patients treated for uncomplicated P. *falciparum* with artesunate for seven days and where there was no evidence of delayed parasitaemia, the median parasitaemia at enrolment (P0) was 27,070 μL and the observed median time of parasite clearance was 32 hours. Applying the suggested method using the logarithmic correlation found in the present paper (pPCT = 3.614\*ln(P0) -- 6.135) gave very similar results (30.8 hours with intervals of 26.8 to 37.3 hours).

This simple method was tested to predict a "typical" PCT in situations when resistance has not emerged. However, this estimation of the predicted time to parasite clearance is not without its limitations. The calculations may lack precision with studies sampling once a day and at variable intervals from treatment intake (as it might be the case for most clinical trials, especially on the first day). It has been suggested that parasite clearance rate can only be accurately estimated if sampling is at least every six hours \[[@B43]\]; it is thus possible that data could have been "over-analysed" in generating predicted time of parasite clearance in this case. Although parasite clearance half-life is the research reference to define slow parasite clearance, sampling patients four times or even twice a day is not feasible in routine monitoring, and might be cumbersome even in research settings. Detecting the first signs of artemisinin resistance in uncomplicated *P. falciparum* will likely require a combination of more sophisticated studies and routine monitoring. Between parasite clearance estimators \[[@B9]\] and Day 3 persistency \[[@B10]\], simple estimations of PCT based on daily sampling may add elements to facilitate comparisons and detection of trends. It would be useful to compare methods for validation, including databases with delayed responses.
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